Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 7,077 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

NCT03106415
View directory record Official record
Conditions
Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Binimetinib, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 28, 2026, 9:30 PM EDT
Completed No phase listed Observational

The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer

NCT02167932
View directory record Official record
Conditions
Breast Cancer, Aging
Interventions
Walk With Ease
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years to 59 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

NCT03414684
View directory record Official record
Conditions
Breast Cancer
Interventions
Carboplatin, Nivolumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Stamford, Connecticut • Bangor, Maine • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Cancer Screening and Follow-up in Community Health Centers

NCT05756725
View directory record Official record
Conditions
Breast Cancer Screening, Colorectal Cancer Screening, Implementation
Interventions
Practice-Level Implementation Strategies
Other
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Biloxi, Mississippi • Hartsville, South Carolina • Appleton, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 28, 2026, 9:30 PM EDT
Recruiting Phase 2 Interventional

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
8
States / cities
Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

NCT00455533
View directory record Official record
Conditions
Breast Cancer
Interventions
Ixabepilone, Paclitaxel, Cyclophosphamide, Doxorubicin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Palm Springs, California • Coral Spring, Florida • Davie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 28, 2026, 9:30 PM EDT
Recruiting Not applicable Interventional

CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer

NCT06915168
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Informational Intervention, Survey Administration
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Internet Use Among Women With Recurrent Metastatic Breast Cancer

NCT00770055
View directory record Official record
Conditions
Breast Cancer
Interventions
medical chart review, questionnaire administration, survey administration, psychosocial assessment and care
Other · Procedure
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2011 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Radiofrequency Chip for Localization of Non-Palpable Breast Lesions

NCT03684408
View directory record Official record
Conditions
Breast Tumor
Interventions
RFID Localization, Wire Localization, RFID and Wire Localization
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 28, 2026, 9:30 PM EDT
Completed No phase listed Observational

Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients

NCT01639417
View directory record Official record
Conditions
Pain, Breast Cancer
Interventions
Not listed
Lead sponsor
Lynn Henry
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 28, 2026, 9:30 PM EDT
Terminated Phase 1 Interventional

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

NCT03955640
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma
Interventions
Olaparib, Hyperthermia Treatment, Questionnaire Administration, Quality-of-Life Assessment
Drug · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 28, 2026, 9:30 PM EDT
Not listed Phase 2 Interventional

Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

NCT01283789
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lapatinib and RAD-001
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

NCT00005991
View directory record Official record
Conditions
Breast Cancer
Interventions
gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 28, 2026, 9:30 PM EDT
Completed No phase listed Observational

MammoVerse: Breast Cancer Sexual Health Focus Groups

NCT07644858
View directory record Official record
Conditions
Breast Cancer
Interventions
Questionnaires and Focus Group
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Recruiting Not applicable Interventional

A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New York

NCT06833255
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Interview, Questionnaire Administration, Support, Support Group Therapy
Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

NCT00003125
View directory record Official record
Conditions
Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ALVAC-CEA vaccine, aldesleukin, sargramostim, vaccinia-CEA vaccine
Biological
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 28, 2026, 9:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

NCT07441889
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
HER2 FPBMC
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Recruiting Phase 1 Interventional

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674
View directory record Official record
Conditions
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
Interventions
NX-1607, Paclitaxel
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Improving Cancer Outcomes Through Personalized Care Planning and Symptom Management.

NCT04772118
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Gynecologic Cancer
Interventions
Carevive PROmpt™
Other
Lead sponsor
Carevive Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 28, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

NCT01120184
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin], trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
62
States / cities
Little Rock, Arkansas • La Jolla, California • Montebello, California + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 28, 2026, 9:30 PM EDT
Recruiting Phase 3 Interventional

Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Tissue Nanomechanical Phenotype Evaluation

NCT05774678
View directory record Official record
Conditions
Breast Cancer
Interventions
Group 1 (preoperative radiation hypofractionated), Group 2 (preoperative radiation conventionally fractionated)
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 9:30 PM EDT
Terminated No phase listed Observational

Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer

NCT03057743
View directory record Official record
Conditions
METASTATIC BREAST CANCER
Interventions
Positron emission tomography (PET/CT) imaging, radiotracer [18F]ISO-1
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 28, 2026, 9:30 PM EDT
Completed No phase listed Observational

Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer

NCT00489125
View directory record Official record
Conditions
Breast Cancer
Interventions
physiologic testing
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 28, 2026, 9:30 PM EDT
Terminated Phase 1Phase 2 Interventional

ABI-008 Trial in Patients With Metastatic Breast Cancer

NCT00531271
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ABI-008 (nab-docetaxel)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 28, 2026, 9:30 PM EDT